Several brokerages have updated their recommendations and price targets on shares of Sanofi (NYSE: SNY) in the last few weeks:

  • 9/15/2016 – Sanofi had its “underweight” rating reaffirmed by analysts at JPMorgan Chase & Co..
  • 9/14/2016 – Sanofi had its “hold” rating reaffirmed by analysts at Jefferies Group.
  • 9/13/2016 – Sanofi was upgraded by analysts at BNP Paribas from an “underperform” rating to a “neutral” rating.
  • 9/8/2016 – Sanofi was upgraded by analysts at Berenberg Bank from a “hold” rating to a “buy” rating.
  • 8/22/2016 – Sanofi was downgraded by analysts at TheStreet from a “buy” rating to a “hold” rating.
  • 8/15/2016 – Sanofi had its “hold” rating reaffirmed by analysts at Berenberg Bank. They now have a $93.00 price target on the stock.
  • 8/3/2016 – Sanofi was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Although Sanofi posted in-line earnings in Q2, both earnings & revenues were down y/y. The Diabetes franchise is under significant pressure with key product, Lantus, facing increasing competitive pressure at the payor level and the presence of biosimilar competition in several European markets & Japan. Moreover, a biosimilar version of Lantus could hit the U.S. markets by the end of 2016. Sanofi’s outlook for its Diabetes franchise over the 2015–2018 timeframe is also bleak. Other headwinds include generic competition and slower-than-expected uptake of new products like Praluent. However, Sanofi's focus on streamlining its business and pursuing business development deals is encouraging. Sanofi is looking to acquire oncology-focused company Medivation, which has a blockbuster product, Xtandi. Sanofi’s pipeline continues to progress – products like Toujeo, Aubagio and Lemtrada should do well.”
  • 7/27/2016 – Sanofi was upgraded by analysts at TheStreet from a “hold” rating to a “buy” rating.
  • 7/25/2016 – Sanofi was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Sanofi possesses a diversified product portfolio with a presence in several therapeutic areas including cardiovascular diseases, diabetes, oncology, and CNS disorders, among others. New products like Toujeo, Aubagio and Lemtrada should do well. The company has a robust pipeline and expects a lot of activity on this front in 2016. Moreover, Sanofi’s focus on streamlining its business and pursuing business development deals is encouraging. Sanofi is currently looking to acquire oncology-focused company Medivation, which has a blockbuster product, Xtandi, in its portfolio. However, Sanofi’s Diabetes franchise continues to face increasing competitive pressure and biosimilar competition in several European markets. Moreover, the outlook for the Diabetes business over the 2015–2018 period is disappointing. Other headwinds include generic competition and slower-than-expected uptake of new products like Praluent.”

Sanofi (NYSE:SNY) traded down 1.578% during midday trading on Wednesday, hitting $38.355. The stock had a trading volume of 2,810,094 shares. The stock has a market cap of $98.73 billion, a P/E ratio of 21.267 and a beta of 1.01. The company has a 50-day moving average price of $39.51 and a 200-day moving average price of $40.65. Sanofi has a 52 week low of $37.41 and a 52 week high of $51.88.

Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets, diabetes solutions, vaccines, consumer health care, animal health, genzyme and other products.

5 Day Chart for NYSE:SNY

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.